Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Primary disease is leukemia or MDS.~2. Patients receive haploidentical stem cell transplantation.~3. Both patients and donors are CMV seropositive (IgG positive).~4. Subjects must be capable of, and willing to provide written informed consent to participate in the study. Subjects unable to provide written informed consent by themselves may be consented through their legal representative.~Exclusion Criteria:~1. Participation in another industry-sponsored clinical study where treatment for CMV is already specified by the study protocol.~2. Patients received other adoptive immunotherapy such as donor lymphocyte infusion (DLI), Epstein-Barr virus (EBV)-specific T cells and so on.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Donor-derived CMVpp65-specific T cells (Type: EXPERIMENTAL): Intervention to be adminstered is about 1 million per kg CMVpp65-specific T cells infusion once acute GVHD ocurred post haploidentical transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).